Tolerogenic dendritic cells in type 1 diabetes: no longer a concept

Area of Science:

• Immunology
• Endocrinology
• Cell Therapy

Background:

• Autoimmune-driven dysglycemia can progress to insulin-requiring type 1 diabetes (T1D).
• Tolerogenic dendritic cells (tDC) are generated ex vivo from peripheral blood leukocytes.
• Phase I clinical studies have demonstrated the safety of tDC therapy.

Purpose of the Study:

• To review the current status of tDC therapy for type 1 diabetes.
• To explore the mechanisms of immune regulation employed by tDC.
• To propose future directions for tDC generation and clinical application in T1D.

Main Methods:

• Review of existing clinical data and research on tDC therapy for T1D.
• Analysis of tDC phenotypes and mechanisms of action across different generation methods.
• Proposal for combination therapy involving tDC and T-regulatory cells (Tregs).

Main Results:

• tDC can arrest T1D progression and preserve pancreatic beta cell mass.
• tDC exert immune regulation by targeting effector lymphocytes.
• tDC exhibit conserved mechanisms of action regardless of generation method.

Conclusions:

• The safety and efficacy data support advancing tDC into Phase II clinical trials for T1D.
• Standardizing tDC generation methods and refining purity markers are crucial.
• Co-administration or serial alternation of tDC and Tregs may offer synergistic therapeutic benefits for T1D.